These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12391962)

  • 1. Evaluation of biotechnology-based healthcare products for prioritization in Indian context.
    Visalakshi S; Mohan S
    Int J Technol Assess Health Care; 2002; 18(3):718-27. PubMed ID: 12391962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Policy and ethical issues in applying medical biotechnology in developing countries.
    Bhardwaj M; Macer DR
    Med Sci Monit; 2003 Feb; 9(2):RA49-54. PubMed ID: 12601306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical context of technology assessment.
    Smits HL
    J Health Polit Policy Law; 1984; 9(l):31-40. PubMed ID: 11650667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priority setting and the ethics of resource allocation within VA healthcare facilities: results of a survey.
    Foglia MB; Pearlman RA; Bottrell MM; Altemose JA; Fox E
    Organ Ethic; 2008; 4(2):83-96. PubMed ID: 18839751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology prioritization: which criteria for prioritizing new technologies and what are their relative weights?
    Golan O; Hansen P; Kaplan G; Tal O
    Health Policy; 2011 Oct; 102(2-3):126-35. PubMed ID: 21071107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis.
    Brandeau ML; Zaric GS; Richter A
    J Health Econ; 2003 Jul; 22(4):575-98. PubMed ID: 12842316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
    Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
    Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining products for a new health technology assessment agency in Madrid, Spain: a survey of decision makers.
    Andradas E; Blasco JA; Valentín B; López-Pedraza MJ; Gracia FJ
    Int J Technol Assess Health Care; 2008; 24(1):60-9. PubMed ID: 18218170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical context of technology assessment.
    Smits HL
    J Health Polit Policy Law; 1984; 9(1):31-40. PubMed ID: 6736598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biotechnology and animal health].
    Desmettre P
    Rev Sci Tech; 1993 Jun; 12(2):355-68. PubMed ID: 8400382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis and innovation.
    Jena AB; Philipson TJ
    J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.